This Project Grant award of $1,558,753.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of Cincinnati in conducting tissue engineering research for cutaneous and systemic epidermolysis bullosa gene therapy. The award period runs from September 1, 2023 to August 31, 2026.
The University of Cincinnati, through its Sponsored Research Services Division, is the prime awardee on this grant. As a subcontractor, the University of California, Davis will provide specialized research services and support to the project. The overarching goal is to advance innovative medical solutions for treating epidermolysis bullosa, a rare genetic disorder affecting the skin and other organs.
Generated 5/7/24, 10:48 AM